SAVA, GIANNI
 Distribuzione geografica
Continente #
NA - Nord America 18.868
EU - Europa 9.215
AS - Asia 2.864
SA - Sud America 56
AF - Africa 37
Continente sconosciuto - Info sul continente non disponibili 30
OC - Oceania 13
Totale 31.083
Nazione #
US - Stati Uniti d'America 18.821
UA - Ucraina 1.900
SE - Svezia 1.859
CN - Cina 1.127
PL - Polonia 1.118
DE - Germania 1.086
IT - Italia 963
SG - Singapore 747
FI - Finlandia 572
HK - Hong Kong 490
GB - Regno Unito 460
TR - Turchia 338
RU - Federazione Russa 304
BG - Bulgaria 301
IE - Irlanda 289
FR - Francia 146
CH - Svizzera 53
IN - India 43
CA - Canada 34
BE - Belgio 31
KR - Corea 31
EU - Europa 30
BR - Brasile 28
SN - Senegal 23
NL - Olanda 21
RO - Romania 17
VN - Vietnam 17
BA - Bosnia-Erzegovina 14
CL - Cile 14
SA - Arabia Saudita 12
TH - Thailandia 12
PT - Portogallo 11
AT - Austria 10
CZ - Repubblica Ceca 10
RS - Serbia 10
EG - Egitto 9
ID - Indonesia 9
MX - Messico 9
DK - Danimarca 8
MY - Malesia 7
NZ - Nuova Zelanda 7
AU - Australia 6
GR - Grecia 6
HR - Croazia 6
IR - Iran 6
JP - Giappone 6
AR - Argentina 5
ES - Italia 5
HU - Ungheria 5
GE - Georgia 4
VE - Venezuela 3
BO - Bolivia 2
CO - Colombia 2
IL - Israele 2
LB - Libano 2
MA - Marocco 2
MD - Moldavia 2
NO - Norvegia 2
PK - Pakistan 2
QA - Qatar 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
DO - Repubblica Dominicana 1
FK - Isole Falkland (Malvinas) 1
GT - Guatemala 1
HN - Honduras 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
LT - Lituania 1
LU - Lussemburgo 1
MN - Mongolia 1
NI - Nicaragua 1
PE - Perù 1
TN - Tunisia 1
ZA - Sudafrica 1
Totale 31.083
Città #
Woodbridge 2.448
Ann Arbor 2.360
Fairfield 1.902
Houston 1.682
Jacksonville 1.639
Chandler 1.266
Warsaw 1.104
Wilmington 1.102
Ashburn 1.022
Seattle 827
Cambridge 647
Singapore 632
Princeton 574
Hong Kong 481
Boardman 476
Beijing 379
Sofia 301
Columbus 290
Dublin 286
Izmir 277
Dearborn 217
Trieste 164
San Diego 134
Milan 107
Santa Clara 89
Düsseldorf 79
Chicago 64
Hefei 61
Falls Church 54
Verona 53
Kocaeli 51
Norwalk 47
Redwood City 46
Bern 43
Kunming 43
Bremen 41
Buffalo 41
Nanjing 41
Mestre 39
Phoenix 34
Des Moines 32
Guangzhou 32
Jinan 32
Shanghai 30
Brussels 27
Dakar 23
Seoul 23
Helsinki 22
Andover 19
Fuzhou 17
Dallas 16
Nanchang 16
Auburn Hills 15
Los Angeles 15
Ottawa 15
Redmond 15
Shenyang 15
Dong Ket 14
Hangzhou 14
Hebei 14
Sarajevo 13
Zhengzhou 13
Fremont 11
Chengdu 10
Mountain View 10
New York 10
São Paulo 10
Poplar 9
Changsha 8
Chongqing 8
Indiana 8
Munich 8
Vienna 8
Baotou 7
Costa Mesa 7
Grafing 7
Jiaxing 7
North Bergen 7
Tappahannock 7
Wuhan 7
Xian 7
Brno 6
Chaoyang 6
Chennai 6
Lisbon 6
London 6
Polska 6
Pune 6
Riyadh 6
Rome 6
Tianjin 6
Washington 6
Wenzhou 6
Al Kharj 5
Amsterdam 5
Athens 5
Atlanta 5
Cardiff 5
Dongguan 5
Kolkata 5
Totale 21.838
Nome #
Effects of Two Fullerene Derivatives on Monocytes and Macrophages 403
Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin 310
Pharmacological activities of ruthenium complexes related to their NO scavenging properties 290
Identification and Characterization of a Novel Family of Cysteine-Rich Peptides (MgCRP-I) from Mytilus galloprovincialis 283
Chemical and Molecular Approach to Tumor Metastases 276
The differential distribution of RAPTA-T in non-invasive and invasive breast cancer cells correlates with its anti-invasive and anti-metastatic effects 250
A Cationic [60] Fullerene Derivative Reduces Invasion and Migration of HT-29 CRC Cells in Vitro at Dose Free of Significant Effects on Cell Survival 223
Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A 210
New salts of anionic complexes of Ru(III) as antimetastatic and antineoplastic agents. 206
Sulfoxide ruthenium complexes: non toxic tools for the selective treatment of solid tumour metastases. 190
Analysis of the cytotoxicity of synthetic antimicrobial peptides on mouse leucocytes: implications for systemic use. 188
The antimetastatic drug NAMI-A potentiates the phenylephrine-induced contraction of aortic smooth muscle cells and induces a transient increase in systolic blood pressure 181
Response of MCa mammary carcinoma to cisplatin and to Na[trans-RuCl4(DMSO)(Im)]. 178
Reduction of lung metastases by Na[trans-RuCl4(DMSO)Im] is not coupled with the induction of chemical xenogenization 176
Efficacy of 5-FU combined to Na[trans-RuCl4(DMSO)(Im)], a novel selective antimetastatic agent, on the survival time of mice with P388 leukemia, P388/DDP subline and MCa mammary carcinoma 168
trans-Ru(II)dimethylsulfoxides: antineoplastic action on mouse tumors 165
A novel retinoic/butyric hyaluronan ester for the treatment of acute promyelocytic leukemia: preliminary preclinical results 164
Tumor inhibition and effects on host survival time by rutheniumIII andrhodiumIII complexes with dimethylsulphoxide ligands. 162
Complessi dicarbossilati del rutenio(II) e loro impiego come antitumorali 161
Ruthenium(III) complexes as antineoplastic agents. 160
Chemical, biological and antitumor properties of ruthenium(II) complexes with dimethylsulfoxide 160
Rhodium(III) analogues of antitumour-active ruthenium(III) compounds: the crystal structure of [ImH][trans-RhCl4(Im)2] (Im= imidazole) 159
Hydrophilic polymer coated monodispersed Fe3O4 nanostructures and their cytotoxicity 159
Antitumor action of mer-trichlorobis(dimethyl sulfoxide)aminoruthenium(III) (BBR2382) in mice bearing Lewis lung carcinoma 157
Investigation on the oxidative N-demethylation of aryltriazenes in vitro 157
Effects of lysozyme on spleen and lungs in mice with Lewis lung carcinoma 156
Reconsidering clinical pharmacology frameworks as a necessary strategy for improving the health care of patients: a systematic review 156
Complessi trans di rutenio come agenti antineoplastici 153
Antitumor and antimetastatic effects of benzenoid triazenes in mice bearing Lewis lung carcinoma. 153
Antiinflammatory action of hydrosoluble dimethyltriazenes on the carrageenin-induced edema in guinea pigs 153
Antitumor effects of rhodium(I), iridium(I) and ruthenium(II) complexes in comparison with cis-dichloro-diamminoplatinum(II) in mice bearing Lewis lung carcinoma 153
The mechanism of tumour cell death by metal-based anticancer drugs is not only a matter of DNA interactions 151
Effects of antimetastatic, antiinvasive and cytotoxic agents on the growth and spread of transplantable leukemias in mice. 150
Na[trans-RuCl4(DMSO)(Im)]*2DMSO - antimetastatic ruthenium agent 148
RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A 148
Ruthenium-Porphyrin Conjugates with Cytotoxic and Phototoxic Antitumor Activity 147
Biochemical and biological characteristics of leucocyte proteinase inhibitors. 147
Ruthenium complexes can target determinants of tumour malignancy 146
In vitro and in vivo evaluation of ruthenium(II)-arene PTA complexes 146
Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy 146
Human recombinant lysozyme downregulates advanced glycan endproduct-induced interleukin-6 production and release in an in vitro model of human proximal tubular epithelial cells 145
Effects of trans-RuCl2 (DMSO)4 on B16 melanoma in mice. 144
The development of tumor-inhibiting ruthenium dimethylsulfoxide complexes 144
In vivo tumour and metastasis reduction and in vitro effects on invasion assays of the ruthenium RM175 and osmium AFAP51 organometallics in the mammary cancer model 144
Down-regulation of tumour gelatinase/inhibitor balance and preservation of tumour endothelium by an antimetastatic ruthenium complex 143
Can peptides be orally-delivered in crustaceans? The case study of the Crustacean Hyperglycaemic Hormone in Procambarus clarkii 143
Antitumor properties of ruthenium(II)-dimethylsulfoxide complexes in the Lewis lung carcinoma system 142
Antimetastatic effects and tumor proteinase inhibition by spleen intracellular inhibitors of neutral proteinases. 141
Pharmacological aspects and therapeutic applications of lysozymes 141
Effects of ruthenium complexes on experimental tumors: irrelevance of cytotoxicity for metastasis inhibition 140
Reduction of B16 melanoma metastases by oral administration of egg-white lysozyme 140
Antimetastatic action of the prostacyclin analog Iloprost in the mouse 140
Influence of the anionic ligands on the anticancer activity of Ru(II)-dmso complexes: Kinetics of aquation and in vitro cytotoxicity of new dicarboxylate compounds in comparison with their chloride precursors 140
Antineoplastic activity and toxicity of an organometallic complex of ruthenium(II) in comparison with cis-PDD in mice bearing solid malignant neoplasms 139
Comparison of the effects of the antimetastatic compound ImH[trans-RuCl4(DMSO)Im] (NAMI-A) on the arthritic rat and on MCa mammary carcinoma in mice 139
Na[trans-RuCl4(DMSO)Im], a metal complex of ruthenium with antimetastatic properties 139
Effects of endotoxin in mice bearing solid metastasizing tumors and treated with lysozyme hydrochloride 139
Inhibition of B16 Melanoma Metastases with the Ruthenium Complex Imidazolium trans-Imidazoledimethylsulfoxide-tetrachlororuthenate and Down-Regulation of Tumor Cell Invasion. 137
Lysozyme induced recovery of the response to ConA on mononuclear cells harvested from mice bearing MCa mammary carcinoma 137
Orally administered microencapsulated lysozyme downregulates serum AGE and reduces the severity of early-stage diabetic nephropathy 136
Antimetastatic effects of N-diazoacetyl-glycine derivatives in C57BL mice. 136
Methodologic problems encountered in the assay of proteinases in Lewis lung carcinoma, a mouse metastasizing tumor. 136
Metal-Based Inhibition of Poly(ADP-ribose) Polymerase - The Guardian Angel of DNA 136
Free exchange across cells,and echistatin-sensitive membrane target for the metastasis inhibitor NAMI-A(imidazolium trans-imidazole dimethyl sulfoxide tetrachlororuthenate)ON KB Tumor cells. 134
Effects of L-(adamant-2-yl)glycyl-L-alanyl-D-isoglutamine on the antitumor action of cyclophosphamide, 5-FU, cisplatin and dacarbazine on advanced carcinomas of the mouse 134
Treatment of metastases of solid mouse tumours by NAMI-A: comparison with cisplatin, cyclophosphamide and dacarbazine 134
Distinct effects of dinuclear ruthenium(III) complexes on cell proliferation and on cell cycle regulation in human and murine tumor cell lines. 133
Inhibitory Effects of the Ruthenium Complex KP1019 in Models of Mammary Cancer Cell Migration and Invasion 133
Tumour metastatic potential after treatment with selective antimetastatic drugs 133
Neutral proteinase inhibitors and antimetastatic effects in mice. 132
Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs 132
Evidence for host-mediated antitumor effects of lysozyme in mice bearing MCa mammary carcinoma 132
Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound 131
Down-regulation of tumor gelatinase/inhibitor balance and preservation of tumor endothelium by an anti-metastatic ruthenium complex. 131
Antileukemic action of RuCl2(DMSO)4 isomers and prevention of brain involvement on P388 leukemia and on P388/DDP subline 131
Antitumor effects of GANU and other nitrosourea derivatives against transplantable leukemias and solid tumors in mice. 131
Mechanism of the antimetastatic action of N-diazoacetylglycinamide in mice bearing Lewis lung carcinoma. 131
null 130
Antineoplastic effects of mer-RuCl3(DMSO)2(NH3) against murine tumors: comparison with cisplatin and with ImH[RuIm2Cl4]. 129
Effects of p-(3,3-dimethyl-1-triazeno) benzoic acid potassium salt on leukemic infiltration of brain and liver in mice bearing P388 leukemia. 129
Influence of the binding of reduced NAMI-A to human serum albumin on the pharmacokinetics and biological activity 129
Tuning the hydrophobicity of ruthenium(ii)-arene (RAPTA) drugs to modify uptake, biomolecular interactions and efficacy 128
Ruthenium-sulfoxide complexes with a specific antimetastatic activity 128
Study of a potential drug delivery system based on carbon nanoparticles: Effects of fullerene derivatives in MCF7 mammary carcinoma cells 128
Ruthenium drugs for cancer chemotherapy: an ongoing challenge to treat solid tumours 128
Microencapsulation of Bioactive Principles with an Airless Spray-Gun Suitable for Processing High Viscous Solutions 128
Complessi di Rutenio con elevata attività antitumorale 127
Effects of isomeric aryldimethyl-triazenes on Lewis lung carcinoma growth and metastases in mice 127
Cis- and trans-dihalotetrakis(dimethylsulfoxide)Ruthenium(II) Complexes (RuX2(Me2SO)4; X = Cl, Br): Synthesis, Structure and Antitumor Activity 126
Metal complexes of platinum group: the promising antitumor features of cis-dichlorotetrakis(dimethylsulfoxide)Ru(II) (cis- RuCl2(DMSO)4) and related complexes 126
Profiling the molecular mechanism of fullerene cytotoxicity on tumor cells by RNA-seq 126
Recovery of lymphocyte CD4+:CD8+ ratio in patients treated with lysozyme 125
Synthesis and characterization of a diruthenium(II,III)-ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives 125
Antimetastatic Action and Lymphocyte Activation by the Modified Lysozyme Lyso-M-PEG in Mice with Mca Mammary Carcinoma 125
Actin-dependent tumour cell adhesion after short-term exposure to the antimetastasis ruthenium complex NAMI-A 124
Effects of NAMI-A and some related ruthenium complexes on cell viability after short exposure of tumor cells. 124
Platinum(II) complexes with antitumoral/antiviral aromatic heterocycles: effect of glutathione upon in vitro cell growth inhibition 122
Metal-based antitumour drugs in the post genomic era 121
Synthetic thymic fraction 5: Effects of high dose administration on circulating lymphocytes in patients 121
Antitumour properties of dimethylsulphoxide ruthenium (II) complexes in theLewis lung carcinoma system. 120
Totale 15.358
Categoria #
all - tutte 87.078
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 87.078


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20204.167 0 0 0 0 400 823 628 804 529 343 492 148
2020/20214.217 425 164 381 626 271 498 200 381 199 490 136 446
2021/20223.230 103 253 187 463 49 257 137 116 386 345 200 734
2022/20233.888 426 429 284 486 445 737 9 354 474 23 158 63
2023/20241.932 163 134 109 112 221 92 245 504 29 35 141 147
2024/20251.560 96 157 510 422 375 0 0 0 0 0 0 0
Totale 31.785